Precigen (NASDAQ:PGEN) Trading Up 8.4% – What’s Next?

Shares of Precigen, Inc. (NASDAQ:PGEN) traded up 8.4% during trading on Tuesday . The stock traded as high as $2.03 and last traded at $2.13. 502,453 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 2,153,742 shares. The stock had previously closed at $1.96.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on PGEN shares. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.00.

Precigen Stock Down 3.0 %

The firm has a market capitalization of $576.95 million, a PE ratio of -3.58 and a beta of 1.66. The stock has a 50-day moving average price of $1.23 and a 200 day moving average price of $1.05.

Institutional Investors Weigh In On Precigen

A number of institutional investors have recently modified their holdings of the company. Iridian Asset Management LLC CT increased its position in shares of Precigen by 38.8% during the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock worth $5,871,000 after acquiring an additional 1,465,962 shares during the period. Geode Capital Management LLC increased its holdings in Precigen by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after purchasing an additional 53,343 shares during the period. State Street Corp raised its position in Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after purchasing an additional 29,253 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Precigen by 4.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company’s stock valued at $1,432,000 after buying an additional 56,012 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Precigen by 11.6% in the 4th quarter. Northern Trust Corp now owns 1,168,689 shares of the biotechnology company’s stock valued at $1,309,000 after buying an additional 121,700 shares during the period. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.